Every fact traced to its source, and checked against it. Explore the companies, facts, and conclusions behind the news.
Conclusions our AI is drawing from the traced facts — read them as interpretation, each grounded in the data and the entities it names.
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
In Q3 2026 earnings and announcements, enterprise software vendors are repositioning around AI agents. Salesforce is buying Braze, ServiceNow launched a Control Tower Alliance, Zoom added a Unified Context Layer, and Confluent introduced Streamhouse. Governance, real-time data and orchestration are the main battleground. Investors such as Norwest see room to disrupt ERP and finance software. Small-cap players like TEN Holdings and Tiny are pursuing SaaS pivots and tuck-in acquisitions. Mature industrial software such as Trimble faces a 2027 headwind.
Late-October to early-November 2026 announcements show AI moving into the core of enterprise platforms: Fortinet's inline AI security, Cisco's partner and cloud tooling, Salesforce's Braze acquisition, Intuit's international AI rollout, and NVIDIA RTX Spark hardware. A parallel thread is physical AI and embodied intelligence, where executives (Encord, Harvest Praxis/MediaTek) say the bottleneck is costly data collection and chip architecture. Smaller firms such as TEN Holdings and Impinj show a shift toward SaaS-style models and cost discipline. The set is loosely connected, with little direct finance or regulatory content.
Companies are reshaping boards and leadership as universal proxy rules push activists and boards toward settlements instead of costly proxy contests. Align's planned CEO handover from Hogan to Davis, Oasis's director nominations at Vail Resorts, new board seats at Mineralys and Stride, and wind-downs and deal-driven meetings at Elme, Globa Terra and Odyssey all fit this pattern. A side thread, from Seth Kugler, is that AI use is creating new governance and legal exposure around trade secrets and employee data.
Late October to mid-November 2026 brought steady biotech clinical progress. Vor Biopharma's TELIGAN Phase 3 results, Incyte's ESMO pancreatic cancer data and partnerships, and Eli Lilly's strong GLP-1 demand all stand out. Pipeline companies are also hiring business development and R&D leaders and giving IND and Phase 1 timelines. Early AI-designed therapeutics, such as Radical Numerics' AI-designed viruses and an AI agent that ran a brain injection, are emerging. Meanwhile the wider AI-finance backdrop weakened: a $1 trillion tech selloff, OpenAI cutting its funding target, and $3.6 billion of Binance withdrawals. That weakness raises questions about whether capital for AI-linked biotech will hold up.
ESMO 2026 produced a dense run of oncology news. Incyte (PDAC combinations), Summit/Akeso (ivonescimab), Astellas (CLDN18.2 testing), AstraZeneca (ZEGFROVY launch), Abbott (whole-genome MRD testing) and Novocure (record quarter) all reported progress. At the same time, small and micro-cap players are retrenching: Spago and Medicus are pursuing delistings, SkinJect is going the SPAC route, and ADC Therapeutics is cutting its workforce while guiding to a runway into 2028. The sector is splitting between well-capitalized companies with data and commercial catalysts and capital-starved developers who are leaving public markets or restructuring.
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Samsung will likely announce a unified smart home AI platform or hub within 2-3 months that connects these disparate AI-enabled products
Sustained AI feature expansion across Samsung ecosystem in Q1-Q2 2026, with likely follow-up announcements for mobile devices and additional appliances
NVIDIA GPU acceleration is becoming the dominant infrastructure for AI chip design and EDA workflows, creating a self-reinforcing ecosystem where AI chips are designed using AI-accelerated tools
88% confidence · untestedData center infrastructure investments are shifting from traditional cloud providers to AI-specific facilities, with hyperscalers willing to commit $20B+ multi-year contracts for AI-optimized data center capacity, creating opportunities for specialized infrastructure developers
88% confidence · untestedLLM sycophancy is primarily caused by reinforcement learning from human feedback (RLHF) optimization for user approval rather than truthfulness, creating a systematic bias that degrades model reliability in extended conversations
85% confidence · untestedAI safety concerns are escalating as models gain access to classified and sensitive data, creating new security vulnerabilities and ethical challenges around training data governance
85% confidence · untestedHyperscaler AI infrastructure investments exceeding $200B combined will drive semiconductor demand and AI chip production capacity expansion in 2026
85% confidence · untestedGNQ Insilico Inc. to go Public Through Business Combination With IB Acquisition Corp. (NASDAQ: IBAC)
“GNQ Insilico Inc. to go Public Through Business Combination With IB Acquisition Corp. (NASDAQ: IBAC) BOCA RATON, FL AND TORONTO, ONTARIO, March 16, 2026 (GLOBE NEWSWIRE) -- GNQ Insilico Inc…”
Charlotte's Web outlines Medicare pilot launch with up to $500 per beneficiary annually as BAT converts $55M debenture
“Charlotte's Web outlines Medicare pilot launch with up to $500 per beneficiary annually as BAT converts $55M debenture Earnings Call Insights: Charlotte's Web Holdings (CWEB:CA) Q4 2025 MANAGEMENT VIEW * CEO William Morachnick framed the quarter around a balance-sheet reset and Medicare channel entry: "this is not busi…”
Can Gartner’s AI Strategy Reframe Investor Perceptions After Generation’s Exit From IT?
“Can Gartner’s AI Strategy Reframe Investor Perceptions After Generation’s Exit From IT? Generation Investment Management recently sold its stake in Gartner, Inc., citing concerns that artificial intelligence might be eroding demand for Gartner’s advisory services…”
Bull et Equal1 concluent une alliance stratégique pour accélérer l’intégration hybride quantique-HPC en Europe
“Bull et Equal1 concluent une alliance stratégique pour accélérer l’intégration hybride quantique-HPC en Europe Paris, France – 14 avril 2026 –Bull, leader dans le calcul avancé et l’intelligence artificielle, et Equal1, pionnier mondial de l’informatique quantique sur silicium, annoncent aujourd’hui la signature d’un a…”
Corporate America’s big job cuts in 2026 - What do we know so far?
“Corporate America’s big job cuts in 2026 - What do we know so far? Corporate workers in America have faced the brunt of job cuts since the start of the year…”
Oceaneering projects $390M–$440M EBITDA for 2026 as ADTech drives multiyear growth
“Oceaneering projects $390M–$440M EBITDA for 2026 as ADTech drives multiyear growth Earnings Call Insights: Oceaneering International, Inc…”
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Two different margin values (16% vs 18%) are recorded for the same entity (Shopify Inc.) at the identical timestamp (2026-08-05 00:00:00). With no distinguishing context (same period designation, no qualifier for margin type), these represent conflicting data about the same fact.
Fact B (Q1 2026) and Fact A (Q2 2026) are recorded as observed on the same date: 2026-03-29. This is temporally impossible, since Q2 2026 (April–June) has not yet occurred as of 2026-03-29 (mid-Q1). Financial results for a future period cannot be observed before that period ends. Additionally, 3.7 USD is implausibly low as a cash position for Qualcomm Incorporated, suggesting a data entry error in Fact B.
Both facts measure EPS for Citigroup with identical observation dates (2025-12-31). FACT A explicitly specifies FY 2025 annual EPS at 6.99 USD/share, while FACT B reports 1.65 USD with an unspecified fiscal period (N/A). The values differ by a factor of ~4.2x, which is too large to explain by rounding, methodology, or data quality variance. While FACT B's 'N/A' fiscal period introduces ambiguity about whether it represents the same annual period, both observations are timestamped identically and purport to measure the same metric on the same date. If both represent FY 2025 annual EPS, this is a direct value conflict. If FACT B represents a different period (e.g., quarterly, TTM, or interim), the ambiguous labeling still constitutes a data quality issue that obscures the reconciliation.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Every fact is traceable to the document it came from — see how we source every claim.
Late-October to mid-November 2026 brought a strong Phase 3 kidney result, a Swedish royalty stream still growing, and Incyte cash near $3.3 billion. In the same fortnight a $1 trillion tech selloff hit AI funding. We separate what is verified from what is company-reported.
Oncology news clusters around ESMO in Madrid. Our dossier traces one EU regulatory opinion (Gilead's Trodelvy), a Nordic delisting and verified SEC figures for Summit Therapeutics. Several headline approvals could not be traced to a source, so we leave them out. Press-release sources held up in 53% of checks.
MiCA forced Coinbase to convert non-compliant stablecoins on 30 October, while US venues plan 23-hour trading and Robinhood's event-contract revenue rose more than sixfold to $173M. Robinhood's SEC-filed figures anchor this piece; where sources diverge or are weak, we say so.
Event-contract revenue at Robinhood rose more than sixfold to $173M in Q3, while MiCA pushed Coinbase to convert non-compliant stablecoins. Most of this shift is being decided in the US; Europe's role so far is rule-taker. Figures come from SEC filings and dated documents.
Micron's verified filings show capital spending nearly doubling in a year and cash more than doubling. The European exposure in our data is narrow: ASML, Kalray and Bull. Much of the bullish commentary comes from sources whose past claims held up well under half the time.
Fintech money is moving toward AI-agent identity, payments and trading products. Our dossier is thin on EU specifics, so we say so. What it does hold is checked: Robinhood's SEC-filed results, a $35M identity round, and a Norwest investor's warning that AI should not do the maths.
Robinhood's event-contract revenue rose more than sixfold to $173M in Q3, and Nasdaq, Cboe and the CFTC are all moving toward round-the-clock trading. Europe's visible part in the dossier is MiCA's stablecoin deadline. We checked Robinhood's figures against SEC filings.
Stockholm-based BioArctic's Leqembi royalty rose about 10% in Q2 2026. Idorsia is building its deal-making team. Incyte, Vor and others report data, but the sources vary in reliability, and we flag which claims are measured and which are company statements.
Lam Research guides to an $8.6B quarter on AI chip-equipment demand, while Dow leans on cost cuts against what its CFO calls persistently high energy costs. We checked Dow's multi-year figures against SEC filings. They show why European industry is exposed to the second story, not the first.
Third-quarter calls from Lam Research, Dow and Union Pacific show a split economy. AI-driven chip demand is outrunning supply, while industrials rely on cost cuts against high energy and fuel prices. Dow's comments on European energy costs are the most direct link to European readers. Figures come from SEC-checked data and verbatim call quotes.
Dow told investors that persistently high energy costs challenge European industry economics, while Union Pacific reported fuel costs up 69%. This piece uses fidelity-checked SEC data and named, dated earnings-call quotes. It shows where the dossier is strong and where it is thin on Europe.
Dow's CFO cites $1.1B of quarterly free cash flow and no big debt maturities until 2029, while Union Pacific's fuel bill jumped 69%. Both lean on self-help and balance-sheet strength. Figures come from SEC filings and earnings-call transcripts; the transcript source is reliable only about 60% of the time.
Via News tracked a US-led fintech wave, from retail event contracts to AI-agent identity startups. Little of it is European, and the dossier names no EU regulator. We lead with Robinhood's SEC-checked figures and flag where sources diverge or are weak.
Salesforce, ServiceNow and others are rebuilding around autonomous AI agents, and governance is becoming the selling point. The dossier holds no EU-specific regulatory facts, so we say so. What it does hold is SEC-verified Salesforce financials and primary announcements.
Europe's drug regulator issued positive opinions on RASONQUE, Libtayo dosing and Trodelvy plus Keytruda this summer and autumn, just before ESMO opens in Madrid. SEC-checked figures for Summit Therapeutics show what the pipeline costs. We flag where the evidence is thin or the sources are weak.
Analysts turned more bullish on Palantir in mid-October 2026 while J.P. Morgan's lead defence analyst downgraded Leidos and warned of a weak sector. The dossier holds little European regulatory material, so we say so, and set out what was said, by whom, and how reliable the sources are.
EU regulators backed a new Libtayo dosing schedule and a Trodelvy-Keytruda combination, while US dates for Summit's ivonescimab loom. AstraZeneca's AI drug-design vision rests on forecasts, not results. Summit's checked SEC filings show the cost of a late-stage bet.
Analysts are upgrading Palantir while J.P. Morgan warns on defence stocks. The dossier holds little European-specific evidence, so we say so. We separate verified figures, analyst opinion and our own reading, and flag where the sources are weak.
EU regulators are backing newer cancer treatments, and AI is billed as the long-term engine. But the one company with checked SEC figures, Summit Therapeutics, lost $1.08 billion in FY2025 with no revenue. Several AI claims are forecasts from a source that failed our reliability check.
AI spending is spreading from chips to networking, physical-world data and customer-service software. Nvidia's audited cost of sales shows how fast. The dossier says little about EU rules, and safety scrutiny of OpenAI is rising. Verified filings are separated from company claims.
SAP, Zeta and others are launching agent platforms, while the smaller deals show money flowing to the layers that keep agents in check. Our dossier has little on EU regulation, so we say so. It does contain a clear argument that rules must be enforced by the system, and a warning not to trust AI with finance arithmetic.
A CHMP opinion for Trodelvy, a German-first Optune Pax launch and real-world German data on mogamulizumab give Europe its own oncology story in a US-heavy October. Summit's SEC-verified accounts show how costly the biggest catalyst, ivonescimab, is to reach. Some sources here fared poorly in our reliability checks.
A French networking tie-up and a Dutch equipment maker sit at the European edge of an AI-driven memory and interconnect squeeze. SEC-verified Micron filings show how fast its spending has grown. We separate the checked figures from analyst opinion and flag where the sources are weak.
Three oncology storylines are converging: new-modality drugs nearing decisions, AI-built biologics, and a care-delivery buyout. For European readers the clearest signals are an EMA committee opinion and a Swiss-based device maker's EU launch. Summit's checked SEC filings show what a late-stage bet costs. Source reliability is flagged throughout.
Verified SEC data show Micron's annual capital spending nearly doubled to $15.9bn in fiscal 2025. Meanwhile Nvidia is locking down memory supply, and France's Kalray and Bull are pursuing AI networking. Much of the supporting reporting is only partly reliable, and we show where.
The EU regulator has backed a new first-line breast cancer combination and Novocure has won a CE Mark, while US decisions on ivonescimab and a personalised mRNA vaccine arrive by 14 November. Merck's SEC-verified numbers show cash moving sharply and capex falling. Our sources vary widely in reliability, and we say where.
Every fact here is structured and source-traced — so AI systems inherit ground truth, not re-narrated claims. The same facts a person reads, a model can query.
